When should active surveillance for prostate cancer stop if no progression is detected?
Tiago M de CarvalhoEveline A M HeijnsdijkHarry J de KoningPublished in: The Prostate (2017)
The benefit of AS when compared to CM is strongly dependent on life expectancy and disease risk. Clinicians should take this into account when selecting men to AS, deciding on biopsy frequency and when to stop AS surveillance rounds and transition to CM.